Abstract: Glucose-regulated protein (GRP78) antagonists that block, interfere, and/or inhibit binding of receptor tyrosine kinase orphan receptors (RORs) are described for use as immunotherapy anticancer. These GRP78 antagonists inhibit surface bound GRP78 binding and receptor signaling and are believed to mimic the behavior of anti-angiogenic kringles found in mammalian plasminogen and in receptor tyrosine kinase orphan receptors. These GRP78 antagonist may be free peptide fragments, or peptide fragments covalently fused to blood borne proteins such as albumin or immunoglobins, or modified peptide fragments that a designed to bind to blood or tissue peptides when introduced in vivo into the blood stream of a patient.